本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

BridgeBio Pharma, Inc.

38.57
+0.17000.44%
盘后38.570.00000.00%18:07 EDT
成交量:316.80万
成交额:1.22亿
市值:73.24亿
市盈率:-10.91
高:39.16
开:38.85
低:38.12
收:38.40
数据加载中...
2024/11/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/12

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/11/12

重要事件披露

Form 8-K - Current report
2024/11/06

超过5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2024/09/17

超过5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2024/09/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/09/11

重要事件披露

Form 8-K - Current report
2024/08/21

重要事件披露

Form 8-K - Current report
2024/08/20

超过5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2024/08/20

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/01

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/08/01

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/08/01

重要事件披露

Form 8-K - Current report
2024/07/23

重要事件披露

Form 8-K - Current report
2024/06/24

重要事件披露

Form 8-K - Current report
2024/06/06

重要事件披露

Form 8-K - Current report
2024/06/04

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/05/03

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]